NIH Is Spending $150 Million to Replace Animal Testing. The Implications Go Far Beyond the Lab.

The white mouse has been the default technology of biomedical research for nearly a century. Roughly 111 million animals are used in U.S. laboratory research annually, and mouse models underpin the vast majority of preclinical drug development — despite the uncomfortable fact that 90 percent of drugs that succeed in animal trials fail in human clinical trials. On March 18, 2026, the National Institutes of Health announced $150 million in funding to begin changing that equation, and the implications extend far beyond animal welfare into the core economics and strategy of how research gets funded in America.

The Complement Animal Research in Experimentation program — Complement-ARIE — represents the first major NIH investment in what the agency calls "new approach methodologies," or NAMs: organ-on-chip devices, computational disease models, human tissue constructs, and AI-driven predictive systems designed to replicate human biology more faithfully than animal models ever could. As Granted News reported, this is not a pilot program or a planning exercise. It is a structural commitment with $150 million in initial awards, a public-private validation network, and a $7 million challenge prize co-sponsored by the FDA and EPA.

The Architecture of a $150 Million Bet

Complement-ARIE is structured as a multi-layered initiative designed to move human-based research models from academic curiosity to regulatory-grade tools. The architecture reflects NIH's recognition that the bottleneck is not scientific imagination but institutional infrastructure — the validation standards, data pipelines, and regulatory pathways that allow a new technology to replace an entrenched one.

The first layer is Technology Development Centers (TDCs), which fund multi-year research programs focused on building NAMs for specific disease areas. The initial awards target four categories: gynecological disorders, cardiac disease, neurological disorders, and rare diseases. Each center brings together biomedical engineers, computational scientists, clinicians, and disease specialists to develop models that can predict human drug responses, disease progression, and treatment outcomes without animal intermediaries.

The second layer is the NAMs Data Hub and Coordinating Center (NDHCC), a centralized infrastructure for data sharing, standardization, and quality control across all Complement-ARIE projects. This is the unsexy but essential component — without standardized data formats, reproducibility protocols, and cross-institutional comparison tools, individual NAMs remain isolated laboratory achievements rather than technologies the broader research community can adopt.

The third layer — and potentially the most consequential — is the Validation and Qualification Network (VQN), a public-private partnership that NIH is seeding with approximately $20 million. The VQN connects academic developers with industry partners and regulatory experts whose job is to shepherd NAMs through the FDA qualification process. A human liver-on-chip model that predicts drug toxicity is scientifically interesting; a human liver-on-chip model that the FDA accepts as a valid substitute for animal toxicity studies is commercially transformative. The VQN has already selected four pilot projects focused on preterm birth, developmental neurotoxicity, inhalation toxicity, and acute oral toxicity — areas where current animal models are particularly poor predictors of human outcomes.

The Regulatory Accelerant

Complement-ARIE does not exist in a vacuum. It builds on a regulatory shift that has been accelerating since the FDA Modernization Act 2.0 passed in December 2022, eliminating the requirement that drugs be tested on animals before human clinical trials. That law did not ban animal testing — it removed the mandate, allowing drug developers to use alternative methods if they could demonstrate equivalent or superior predictive value.

The practical challenge since 2022 has been that few alternative methods had the validation track record to satisfy FDA reviewers. Complement-ARIE directly addresses that gap. The FDA's participation in the $7 million NAMs Reduction to Practice Challenge — where research teams must demonstrate that their human-based model works in real-world applications within three years — creates a direct pipeline from NIH-funded development to FDA-accepted methodology.

The EPA's involvement adds another dimension. Environmental health assessments traditionally depend heavily on animal toxicity studies — the standard battery of tests that evaluate whether a chemical causes cancer, organ damage, reproductive harm, or developmental defects in rodents. The EPA has its own strategic plan to reduce animal testing, and the Complement-ARIE challenge provides validated alternatives that could reshape how thousands of chemicals are evaluated under TSCA and other environmental statutes.

This convergence of NIH funding, FDA qualification pathways, and EPA regulatory demand creates what economists call a "market-making" moment — the point at which public investment reduces the risk of adoption enough that private capital begins flowing toward the new technology rather than the old one.

What This Means for Researchers

For biomedical researchers, Complement-ARIE signals a funding trajectory, not just a single program. NIH has announced that it will begin deprioritizing funding opportunities that involve solely animal-based research, shifting resources toward proposals that incorporate human-based methodologies. This does not mean animal research funding disappears overnight — it means the competitive landscape is tilting, and researchers who incorporate NAMs into their grant applications will find increasingly favorable review environments.

The implications vary by career stage and research area. Established investigators with deep expertise in animal models face a strategic inflection point. The skills, colonies, and institutional infrastructure they have built over decades remain valuable in the short term but are depreciating assets in the medium term. The strategic move is to build NAMs expertise alongside existing capabilities — not to abandon animal work immediately, but to ensure that the next R01 renewal incorporates human-based components that position the lab for the funding environment of 2030.

Early-career investigators have a different calculus. Researchers who build their programs around organ-on-chip technology, computational disease modeling, or AI-driven preclinical prediction are entering a field with growing funding, limited competition, and powerful tailwinds from both regulators and funders. The career risk of specializing in a technology that might not pan out is real but declining — the Complement-ARIE investment, combined with the FDA Modernization Act's permissive framework, reduces the probability that NAMs remain a niche.

For translational researchers and companies developing therapeutics, the program creates a parallel track. Drug candidates that demonstrate efficacy and safety through validated NAMs rather than traditional animal models could reach clinical trials faster and at lower cost — particularly for rare diseases where appropriate animal models do not exist or poorly replicate human pathology. Several of the rare disease NAMs being developed through Complement-ARIE TDCs directly address conditions where the absence of good animal models has been a primary barrier to therapeutic development.

The Biotech Funding Angle

Private investment in NAMs technology has been growing but constrained by validation uncertainty. Organ-on-chip companies like Emulate, Hesperos, and TissUse have raised significant venture capital, but pharmaceutical companies have been slow to adopt the technology at scale because the regulatory pathway for substituting animal data with organ-on-chip data remained unclear.

Complement-ARIE changes that calculation by providing the validation infrastructure that de-risks adoption. When the VQN produces FDA-qualified NAMs for specific toxicity endpoints, pharmaceutical companies will have regulatory permission to replace animal studies with human-based alternatives — reducing both the cost and timeline of preclinical development. The commercial market for validated, FDA-qualified NAMs is projected to grow substantially as each new qualification opens up a specific category of animal testing for replacement.

For small businesses and startups in the NAMs space, the program creates several funding pathways beyond the direct Complement-ARIE awards. NIH SBIR and STTR programs increasingly prioritize human-based research tools, and the validation work coming out of the TDCs and VQN creates a technical foundation that small companies can build commercial products on top of. The $7 million Reduction to Practice Challenge is a direct entry point for companies with working prototypes that need real-world validation data.

The Deeper Stakes

Beyond the dollars and the deadlines, Complement-ARIE represents a philosophical pivot in how the world's largest funder of biomedical research defines scientific rigor. For decades, "rigorous preclinical evidence" effectively meant "tested in animals." That definition is being rewritten — not by activists or politicians, but by the scientific evidence that animal models frequently fail to predict human outcomes and by the emergence of technologies that can do better.

The $150 million is a down payment. If the TDCs produce working disease models, the NDHCC establishes reliable data standards, and the VQN qualifies NAMs for regulatory use, the follow-on funding will be substantially larger. NIH Common Fund programs are designed to prove concepts that individual institutes then scale — and the market of animal research that could eventually be replaced represents billions in annual spending across NIH, pharmaceutical R&D, and regulatory testing.

For researchers and institutions positioning their next five years of funding strategy, the signal is unambiguous. The question is no longer whether human-based research models will replace animal testing in significant portions of biomedical science — it is how fast, and who captures the funding and commercial opportunity during the transition. Tools like Granted can help you identify the NAMs-related funding opportunities emerging across NIH, NSF, and DOD, and build applications that align with the direction biomedical funding is moving.